Compare Moderna, Inc. (MRNA) vs Toyota Motor Corp (TM) Price & Performance

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

Toyota Motor trades at $188.54, down 0.13% with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 8.53, P/S of 0.74, and consistent earnings beats in recent quarters. Revenue grew to $48.04T in 2025, though net income margin declined to 8.63%. Recent news includes a major vehicle recall affecting 508,000 US vehicles and a 76% surge in Q1 net profit reported on August 4, 2026.

Toyota presents a mixed outlook with attractive valuation metrics and strong profitability offset by recall-related headwinds and China market weakness. The stock offers value opportunity with below-market multiples, but investors face execution risks from quality control issues and regional sales challenges. Analyst consensus leans cautious with 62.5% hold ratings despite no sell recommendations.